Lakewood-Amedex Biotherapeutics Announces Participation In October Conferences

(MENAFN- EIN Presswire)

Lakewood-Amedex CEO Kelvin Cooper, Ph.D., will participate in three October conferences, highlighting the Company's Nu-3 antimicrobial development program.

Lakewood-Amedex will showcase Nu-3 and its Bisphosphocin® antimicrobial technology at the Maxim Growth Summit, ThinkEquity Conference and IDWeek.

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ:LABT)

SARASOTA, FL, UNITED STATES, October 2, 2026 /EINPresswire / -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.

Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at:

Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City. He will also attend and present at the ThinkEquity Conference on October 15, 2026, in New York City. Later in the month, Dr. Cooper will present a poster on Nu-3 preclinical data at IDWeek on October 22, 2026, in Washington, D.C.

Details are as follows:

Event: Maxim Growth Summit
Date: October 13-14, 2026
Location: Hard Rock Hotel, New York City

Event: ThinkEquity Conference
Date: October 15, 2026
Location: The Mandarin Oriental Hotel, New York City
Presentation: Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In- Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers.
Presentation Time: 3:30 pm

Event: IDWeek
Date: October 21-24, 2026
Location: Walter E. Washington Convention Center, Washington, D.C. (Hybrid Format Available)

The conferences provide opportunities for Lakewood-Amedex to engage with members of the investment, biotechnology, and infectious disease communities and highlight the Company's ongoing development programs Bisphosphocin^® antimicrobial technology.

About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin^® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit .

Contacts:

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
...

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
...

Michelle Katsel
(201) 790-3390
...

Additional Contact

David Shapiro
B2i Digital, Inc.
+1 212-579-4844
...
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Other

LABT CEO Kelvin Cooper heads to three October conferences, including Nu-3 presentations.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences News Provided By B2i Digital, Inc. October 02, 2026, 13:48 GMT Share This Article Distribution channels: Banking, Finance & Investment Industry, Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry, Science, Technology

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

MENAFN02102026003118003196ID1111751623